Immusoft, Takeda ink metabolic disorder cell therapy deal

By The Science Advisory Board staff writers

October 13, 2021 -- Immusoft has signed a research and licensing deal with Takeda Pharmaceutical to develop cell therapies for rare inherited metabolic disorders that have manifestations in the central nervous system.

The collaboration will focus on delivering protein therapeutics across the blood-brain barrier. Under the terms of the agreement, Immusoft will receive an undisclosed upfront payment and research funding support. The company is also eligible to receive future option fees and milestone payments with a total potential value of more than $900 million.

Immusoft is eligible for tiered royalties on future products resulting from the partnership, and Takeda would be responsible for further preclinical and clinical development and commercialization.

Codexis, Takeda expand gene therapy collaboration
Codexis has expanded its strategic collaboration and license agreement with Takeda Pharmaceutical for the research and development of an additional gene...
BridGene, Takeda partner to discover drugs using chemoproteomics
BridGene Biosciences has entered a strategic research collaboration and licensing agreement with Takeda Pharmaceutical to establish up to five drug discovery...
Takeda files dengue vaccine for regulatory approval in EU
The European Medicines Agency, an agency in the European Union (EU), has accepted Takeda Pharmaceutical's filing packages for its dengue vaccine candidate...
Evotec, Takeda partner on RNA-targeting drug discovery, development
Evotec has entered into an alliance with Takeda Pharmaceutical with the goal of discovering and developing RNA-targeting small-molecule therapeutics for...
Takeda, IDT help manufacture Janssen COVID-19 vaccine
Takeda and IDT Biologika announced they will support the manufacturing of the Johnson & Johnson COVID-19 vaccine.

Copyright © 2021 scienceboard.net


Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter